Insmed公司公布的最新临床数据显示,其核心产品Arikayce的安全性特征与既往研究结果高度吻合。在持续监测过程中,未出现超出预期的药物不良反应,也未观察到任何新的安全性风险信号。
Insmed公司公布的最新临床数据显示,其核心产品Arikayce的安全性特征与既往研究结果高度吻合。在持续监测过程中,未出现超出预期的药物不良反应,也未观察到任何新的安全性风险信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.